Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage.
about
Clinical review: Special populations--critical illness and pregnancyTranexamic acid for preventing postpartum haemorrhageTranexamic acid for preventing postpartum haemorrhageTranexamic acid for preventing postpartum haemorrhageRecommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative periodRecommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative periodHemostatic resuscitation in postpartum hemorrhage - a supplement to surgery.Recombinant activated factor VII in post partum haemorrhage.Obstetric hemorrhage.Recombinant activated factor VII as a promising adjuvant therapy for postpartum hemorrhage in the practice of obstetric anesthesia: experience from a university hospital in Taiwan.Postpartum hemorrhage: when uterotonics and sutures fail.Hemostatic disorders in women.Surgical management of placenta accreta: to leave or remove the placenta?Finding Meaning in Life Following Emergency Postpartum Hysterectomy: What Doesn't Kill Us Makes Us Stronger.Recombinant activated factor VIIa in a case of pregnancy with acute hepatic failure and massive blood loss.Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study.Preliminary experience with use of recombinant activated factor VII to control postpartum hemorrhage in acute fatty liver of pregnancy and other pregnancy-related liver disorders.Complete resolution of diffuse placenta increta in a primigravida with twin pregnancy: sonographic monitoring.Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center.
P2860
Q21558535-330465CC-7E2D-44B7-84E6-F832F1679FFDQ24187146-71898019-46DC-48B8-8940-F329505E2039Q24236801-5EB16719-4FD9-4ABE-8E36-E3321E2F28A5Q24240284-3451363C-1C9C-4D7C-B0E3-74246ED2E33FQ34492729-D04BDBB3-3A23-437C-A37C-EF2CD6BEEDB4Q34988663-8F81F91A-B469-41C5-A734-D25AE956304FQ35557436-9B1A215E-1038-4F81-9D98-E240AE136EBEQ37443253-63944EDB-7E5A-4951-9C69-A285BF0EB44FQ37888784-92CA303D-1942-42BC-8ACE-D1797D3C556FQ37898741-9A1C23D8-4046-4E62-806C-1D35EE5348CAQ37995094-99C01C11-515B-4876-99B0-BAC1075399AEQ38117734-CE71B817-5713-4CBC-8486-C9088CC025F3Q38174338-B6A47680-9FDE-4D1B-98E3-5C2FBD7CAB01Q41953167-3048202A-2576-4F3D-95AF-36FFC62870E2Q42535601-5B64FD0A-0B2B-447E-B9C4-7E7F376EFD66Q45057598-4FCA9784-BDDB-4DC9-8677-96D7B60900EEQ46908312-EF3EA86E-C7A5-4F00-AEE5-C2D26763E3E4Q48873928-B6E22B78-4635-4328-AFCA-DD67C56CAD3CQ50603071-63A9BD78-49CE-492C-ACF8-5EC82D8974E3
P2860
Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidelines for the use of reco ...... massive obstetric haemorrhage.
@en
Guidelines for the use of reco ...... massive obstetric haemorrhage.
@nl
type
label
Guidelines for the use of reco ...... massive obstetric haemorrhage.
@en
Guidelines for the use of reco ...... massive obstetric haemorrhage.
@nl
prefLabel
Guidelines for the use of reco ...... massive obstetric haemorrhage.
@en
Guidelines for the use of reco ...... massive obstetric haemorrhage.
@nl
P2093
P2860
P1476
Guidelines for the use of reco ...... massive obstetric haemorrhage.
@en
P2093
Claire McLintock
David Somerset
Phillip Popham
Robert Ogle
Stephen Gatt
P2860
P356
10.1111/J.1479-828X.2007.00823.X
P50
P577
2008-02-01T00:00:00Z